Section Arrow
Quote
IOVA.NASDAQ
- Iovance Biotherapeutics
Quotes are at least 15-min delayed:2025/11/04 02:18 EST
Regular Hours
Last
 1.95
-0.02 (-1.02%)
Day High 
2.2 
Prev. Close
1.97 
1-M High
2.41 
Volume 
50.97M 
Bid
1.97
Ask
1.98
Day Low
1.855 
Open
2.155 
1-M Low
1.93 
Market Cap 
712.85M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.16 
20-SMA 2.17 
50-SMA 2.23 
52-W High 12.505 
52-W Low 1.6385 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.21/-0.79
Enterprise Value
758.22M
Balance Sheet
Book Value Per Share
1.93
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
164.07M
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PHIOPhio Pharmaceuticals Corp1.86-0.19-9.27%0.01PE
CRBUCaribou Biosciences2.43+0.01+0.41%-- 
IOVAIovance Biotherapeutics1.95-0.02-1.02%-- 
RXRXRecursion Pharmaceuticals5.44-0.08-1.45%-- 
THARTharimmune Inc.3.2+0.25+8.47%0.03PE
Quotes are at least 15-min delayed：2025/11/04 02:18 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.